Recently added

Secondary resistance to sonidegib is rare in locally advanced basal cell carcinoma

BAURAIN, JEAN-FRANCOIS; Martelli, Serena; Arntz, Ramon; Savoia, Paola; MUÑOZ COUSELO, EVA; Berking, Carola (Wiley, 2025-09)

Impact of SARS-CoV-2 infection on bispecific antibody treatment in patients with B-cell lymphoproliferative disorders

Serna, Angel; Iraola, Josu; Garcia-Herce, Cristina; Falcó Roget, Anna; Navarro Garces, Victor; Jiménez, Moraima; Bosch Schips, Marc; Albasanz Puig, Adaia; Ruiz- Camps, Isabel; Esperalba, Juliana; Cecilia del Carmen, Carpio Segura; Crespo, Marta; IACOBONI, GLORIA; Marin Niebla, Ana; Bosch, Francesc; Abrisqueta, Pau; Antón Pagarolas, Andrés; Andrés Vergés, Cristina (Elsevier, 2025-08-26)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

VHIO - Articles científics: Recent submissions

Secondary resistance to sonidegib is rare in locally advanced basal cell carcinoma

Impact of SARS-CoV-2 infection on bispecific antibody treatment in patients with B-cell lymphoproliferative disorders

From obscurity to opportunity: targeting Neuregulin 1 fusions in solid tumors

Biomarkers of response and resistance to immune checkpoint inhibitors in breast cancer

Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial

Scientia. Dipòsit d'Informació Digital del Departament de Salut

VHIO - Articles científics: Recent submissions

Secondary resistance to sonidegib is rare in locally advanced basal cell carcinoma ﻿

Impact of SARS-CoV-2 infection on bispecific antibody treatment in patients with B-cell lymphoproliferative disorders ﻿

From obscurity to opportunity: targeting Neuregulin 1 fusions in solid tumors ﻿

Biomarkers of response and resistance to immune checkpoint inhibitors in breast cancer ﻿

Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial ﻿

Secondary resistance to sonidegib is rare in locally advanced basal cell carcinoma

Impact of SARS-CoV-2 infection on bispecific antibody treatment in patients with B-cell lymphoproliferative disorders

From obscurity to opportunity: targeting Neuregulin 1 fusions in solid tumors

Biomarkers of response and resistance to immune checkpoint inhibitors in breast cancer

Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial